Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure.
Recently, fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone, has been linked to the pathophysiology of heart failure (HF), thus encouraging us to examine which hemodynamic abnormalities of HF are linked to either serum FGF23 or plasma B-type natriuretic peptide (BNP) levels. We measured both the serum FGF23 and plasma BNP levels in 154 consecutive prospectively enrolled hospitalized HF patients, with an estimated glomerular filtration rate >40 ml min-11.73 m-2, who underwent heart catheterizations and an echocardiogram. The serum FGF23 levels correlated with the diameter of the inferior vena cava and its respiratory changes, whereas the plasma BNP levels did not. Both the plasma BNP and serum FGF23 levels were moderately correlated with the mean pulmonary artery (PA) pressure and pulmonary capillary wedge (PCW) pressure. Interestingly, in patients with an above-median right-atrial (RA) pressure (4 mm Hg), FGF23 levels were correlated with both PA and PCW pressures, but the levels were not correlated in patients with a below-median RA pressure. In contrast, the plasma BNP levels were correlated with both PA and PCW pressures. Finally, serum FGF23 levels, compared with the plasma BNP levels, were more strongly associated with the clinical outcomes in patients with above-median RA pressure. These findings suggested that serum FGF23 levels are predominantly correlated with clinical outcomes, may serve as a biomarker for HF in patients with higher RA pressure, may provide beneficial information for patients with right-sided HF and may represent different clinical information than that provided only by plasma BNP levels.
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.|Department of Cell Biology, National Cerebral and Cardiovascular Center, Suita, Japan.
Miki
M
Imazu
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Hiroyuki
H
Takahama
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Makoto
M
Amaki
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Yasuo
Y
Sugano
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Takahiro
T
Ohara
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Takuya
T
Hasegawa
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Hideaki
H
Kanzaki
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Toshihisa
T
Anzai
Department of Cell Biology, National Cerebral and Cardiovascular Center, Suita, Japan.
Naoki
N
Mochizuki
Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroshi
H
Asanuma
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.|Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan.
Masanori
M
Asakura
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.|Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan.
Masafumi
M
Kitakaze
D000368:Aged; D001794:Blood Pressure / Q000502:physiology*; D004452:Echocardiography; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006333:Heart Failure / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011669:Pulmonary Wedge Pressure; D014682:Vena Cava, Inferior / Q000000981:diagnostic imaging*
C000717427:FGF23 protein, human; D020097:Natriuretic Peptide, Brain; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23
J Am Coll Cardiol. 2006 Feb 21;47(4):742-8
16487838
Am J Kidney Dis. 2009 Jun;53(6):982-92
19339088
Hypertens Res. 2015 Jan;38(1):74-9
25119474
Am J Physiol Heart Circ Physiol. 2014 Nov 15;307(10):H1504-11
25217649
Eur J Heart Fail. 2007 Sep;9(9):872-8
17586090
JACC Heart Fail. 2015 Oct;3(10):829-39
26450001
Eur J Clin Invest. 2012 Jun;42(6):649-56
22150123
J Am Soc Echocardiogr. 2005 Dec;18(12 ):1440-63
16376782
J Heart Lung Transplant. 2005 Mar;24(3):303-9
15737757
J Am Coll Cardiol. 2009 Feb 17;53(7):582-8
19215832
J Am Soc Nephrol. 2010 Sep;21(9):1427-35
20507943
Circulation. 1997 Nov 18;96(10):3737-44
9396478
J Clin Invest. 2011 Nov;121(11):4393-408
21985788
J Am Coll Cardiol. 2009 Feb 17;53(7):589-96
19215833
J Am Soc Nephrol. 2005 Feb;16(2):520-8
15615819
Eur Heart J. 1983 Jan;4 Suppl A:19-28
6220896
N Engl J Med. 1971 Dec 23;285(26):1441-6
5122894
Am Heart J. 2010 Jun;159(6):949-955.e1
20569705
Circulation. 1999 Sep 7;100(10 ):1116-24
10477538
J Clin Invest. 2003 Sep;112(5):683-92
12952917
J Bone Miner Metab. 2012 Mar;30(2):217-21
21898178
Circulation. 2013 Jan 29;127(4):509-16; discussion 516
23357663
Eur Heart J. 2011 Nov;32(21):2688-96
21733911